CA Patent

CA2565941A1 — Improved nsaid composition

Assigned to Equitech Corp · Expires 2005-11-10 · 21y expired

What this patent protects

The invention isdirected to a composition and method for treating acute pain using a composition comprising one or more NSAID~s, a metasilicate and optionally a fatty acid ester resulting in increased absorption of poorly soluble active NSAID~s and increased absorption in suppres…

USPTO Abstract

The invention isdirected to a composition and method for treating acute pain using a composition comprising one or more NSAID~s, a metasilicate and optionally a fatty acid ester resulting in increased absorption of poorly soluble active NSAID~s and increased absorption in suppressed vagal systems. The preferred composition comprises meloxicam on a metasilicate matrix; and one or more of the following: sodium bicarbonate, Gelucire®, and tartaric acid.

Drugs covered by this patent

Patent Metadata

Patent number
CA2565941A1
Jurisdiction
CA
Classification
—
Expires
2005-11-10
Drug substance claim
No
Drug product claim
No
Assignee
Equitech Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.